Eisai's Banzel gets US approval and complete response letter for epilepsy

[C#198800610:Eisai]'santiconvulsant Banzel (rufinamide) has received approval from the US FDA as an adjunctive treatment for of seizures associated with a severe form of epilepsy, Lennox-Gastaut syndrome (LGS), in patients aged four years and older. It will be launched in the US in 2009.